drugset / Trial / NCT07321834
A Study to Evaluate AI-09 In Participants With Glabellar Lines
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Phase 2 clinical study to evaluate the efficacy, safety, and tolerability of AI-09, a Ready-to-Use Liquid Injectable Botulinum Toxin.
Timeline
- Start
- 2025-12-03
- Primary completion
- 2026-02
- Completion
- 2026-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AI-09 | Protein / enzyme biologic | — | Other |
Indications
No indication recorded.